Company

Genfit SA

Headquarters: Loos, France

Employees: 122

XSTU: XUP +5.01% Euronext: GNFT

Market Cap

€263.1 Million

EUR as of Jan. 1, 2026

US$309.0 Million

Market Cap History

Genfit SA Categories

France Healthcare Biotechnology
France Healthcare France Biotechnology

Genfit SA market capitalization over time

Evolution of Genfit SA market cap in the past 5 years

Market capitalizations are calculated from the opening stock price at the beginning of each month.

Market Cap History of Genfit SA

Top Competitors by Market Capitalization

Industry: Biotechnology

Company	Market Cap (USD)
Novo Nordisk	$158.96 B
Vertex Pharmaceuticals Incorporated	$115.92 B
CSL Limited	$95.75 B
Regeneron Pharmaceuticals, Inc.	$82.28 B
Marinomed Biotech AG	$70.11 B

Sector:

Company	Market Cap (USD)
Lilly	$968.50 B
Johnson & Johnson	$499.57 B
AbbVie	$405.28 B
Roche	$332.12 B
UnitedHealth Group	$304.72 B

Detailed Description

Genfit S.A., a biopharmaceutical company, discovers and develops drug candidates and diagnostic solutions for metabolic and liver-related diseases. The company's products include Elafibranor, which is in Phase 3 clinical trial to treat patients with primary biliary cholangitis. It also engages in the development of NIS4 technology for the diagnosis of nonalcoholic steatohepatitis (NASH) and fibrosis. The company has a licensing agreement with Labcorp for the commercialization of NASHnext, a blood-based molecular diagnostic test. Genfit S.A. was incorporated in 1999 and is headquartered in Loos, France.

⛩️ Moltgate

Start charging for serious requests
in minutes.

Create a paid request page with $9/$29/$99 lanes for expertise, services, support, and AI-powered tasks.

Get Started Free

For professionals, services & 🦞 AI agents.